An AI-powered ultrasound platform that automates vascular diagnostics for peripheral artery disease and diabetic foot wounds, delivering lab-grade results in as little as 25 seconds without a specialized sonographer.
Summary
Moonrise Medical is a Hamilton, Ontario-based medtech company building an AI-powered ultrasound platform that automates vascular diagnostics for peripheral artery disease (PAD) and diabetic foot wounds. Its core innovation is the automated measurement of Pedal Acceleration Time (PAT), a clinically validated metric for predicting wound healing and amputation risk, which the company’s software calculates in as little as 25 seconds without requiring a specialized sonographer.
The goal is to move life-saving vascular assessment out of specialized labs and into the hands of nurses, technologists, and even non-clinical staff at the point of care, closing a diagnostic gap that too often goes unaddressed until it’s too late.
Founded in 2021, Moonrise has received $500K from the Ontario Centre of Innovation, investment from Providence Health Care Ventures and MedTech Angels, support from Creative Destruction Lab, and regulatory development assistance through Innovation Factory’s CAMEDA program. The company is currently completing its commercial prototype and QMS in preparation for FDA 510(k) submission.
“We’re not just advancing technology, we’re democratizing access to critical vascular care,” says Adam Gold, Co-Founder and CEO.
Company Snapshot
- Industry: Medical Devices / Vascular Diagnostics
- Sector: Healthcare / Diagnostics / Medical Technology
- Focus: Peripheral Artery Disease & Diabetic Foot Wound Assessment, Point-of-Care Vascular Diagnostics
- Technology: AI-Powered Automated Ultrasound, Pedal Acceleration Time (PAT) Measurement
- Stage: Seed
- Headquarters: Hamilton, ON, Canada
- Website: https://www.moonrisemedical.com/
Portfolio Manager Perspective
“What convinced us that Moonrise isn’t investing a new metric, it is automating one that’s already clinically proven and putting it in reach of any care team.” Chris Yoo, PhD, Portfolio Manager
Company Overview
Moonrise’s platform automates the capture and interpretation of Pedal Acceleration Time, a clinically validated Doppler waveform metric used to predict wound healing outcomes and amputation risk in patients with PAD and diabetic foot wounds. Where this assessment has traditionally required a specialized vascular sonographer working in a dedicated lab, Moonrise’s software is designed to let nurses, technologists, and non-clinical staff generate a reliable PAT measurement in as little as 25 seconds at the point of care.
The underlying metric is backed by more than 25 peer-reviewed publications and has drawn strong endorsement from interventional radiologists and vascular specialists at institutions including Rush University Medical Center and UF Health. The company is now completing its commercial prototype and quality management system as it prepares for FDA 510(k) submission.
The Problem
Roughly 500 people lose a limb in the United States every day, and 40% of amputees never received a vascular workup before surgery. Sonographer shortages make the problem worse: most radiology departments report significant staffing backlogs, which means the specialized imaging needed to catch PAD and predict wound outcomes often isn’t available when it matters most. The result is a preventable, life-altering gap between what clinical evidence says should happen before amputation and what actually happens in practice.
The disparity compounds for the patients least able to absorb it: roughly 70% of lower-limb amputations are preceded by a foot ulcer, marginalized populations face amputation rates roughly three times higher than average, and five-year mortality following amputation runs near 50%. Earlier, more accessible vascular imaging is one of the few levers that can move all three numbers at once.
Why Moonrise Medical Stands Out
Moonrise distinguishes itself through:
- Automated PAT Measurement in Seconds — software calculates a clinically validated vascular metric in as little as 25 seconds, replacing a process that traditionally requires a specialized lab.
- No Specialized Sonographer Required — designed to be operated by nurses, technologists, and non-clinical staff, putting expert-level vascular imaging at the point of care.
- Clinically Validated Metric — Pedal Acceleration Time is supported by more than 25 peer-reviewed publications on its predictive value for wound healing and amputation risk.
- Strong KOL Endorsement — backed by interventional radiologists and vascular specialists at institutions including Rush University Medical Center and UF Health. Sreekumar “Kumar” Madassery, MD, an interventional radiologist at Rush, has called PAT “the future” of vascular assessment.
- Diversified Early Backing — $500K from the Ontario Centre of Innovation, investment from Providence Health Care Ventures and MedTech Angels, and support from Creative Destruction Lab and Innovation Factory’s CAMEDA program.
Why We Invested
Amputation is one of the most devastating and preventable outcomes in vascular medicine, and the data shows the system is failing too many patients before they ever reach the operating room: 500 limb losses a day in the U.S., with 40% of those patients never receiving a vascular workup. Jetstream is drawn to companies that can close a gap of this scale by removing the bottleneck rather than adding to it — in this case, a nationwide shortage of specialized sonographers.
Moonrise’s platform stood out because it doesn’t ask the health care system to train more specialists; it automates a clinically validated metric so existing staff can generate it at the point of care in under half a minute. That metric’s credibility — more than 25 peer-reviewed publications and endorsement from vascular specialists at institutions like Rush University Medical Center and UF Health — gives us confidence in the science, while support from the Ontario Centre of Innovation, Providence Health Care Ventures, MedTech Angels, and Creative Destruction Lab offers meaningful early validation of the team and business.
We see Moonrise Medical as an opportunity to back an early-stage company positioned to close a life-or-limb diagnostic gap, with a scalable platform advancing toward FDA clearance.
Leadership
- Adam Gold – Co-Founder & Chief Executive Officer
- Abubaker Khalifa, MD – Co-Founder & Chief Operating Officer
- Jill Sommerset, RVT – Co-Founder & Chief Scientific Officer
